-$0.34 EPS Expected for Equillium (NYSE:EQ) This Quarter
Wall Street analysts expect Equillium (NYSE:EQ) to announce ($0.34) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Equillium’s earnings, with the lowest EPS estimate coming in at ($0.44) and the highest estimate coming in at ($0.21). The firm is expected to issue its next earnings results on Monday, August 12th.
On average, analysts expect that Equillium will report full year earnings of ($1.50) per share for the current year, with EPS estimates ranging from ($2.05) to ($1.09). For the next financial year, analysts anticipate that the company will post earnings of ($1.84) per share, with EPS estimates ranging from ($2.83) to ($1.34). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that cover Equillium.
Equillium (NYSE:EQ) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04).
Shares of NYSE:EQ traded down $0.07 during midday trading on Monday, reaching $5.44. 15,839 shares of the company were exchanged, compared to its average volume of 28,715. Equillium has a fifty-two week low of $5.12 and a fifty-two week high of $19.69. The stock’s fifty day moving average price is $5.81.
Several large investors have recently modified their holdings of the stock. Edge Wealth Management LLC acquired a new position in shares of Equillium during the 2nd quarter worth about $40,000. Victory Capital Management Inc. boosted its position in shares of Equillium by 7.4% in the 1st quarter. Victory Capital Management Inc. now owns 1,323,381 shares of the company’s stock valued at $10,587,000 after purchasing an additional 90,792 shares during the period. Deutsche Bank AG acquired a new stake in shares of Equillium in the 4th quarter valued at about $54,000. FMR LLC acquired a new stake in shares of Equillium in the 4th quarter valued at about $6,994,000. Finally, Partner Fund Management L.P. acquired a new stake in shares of Equillium in the 4th quarter valued at about $11,049,000.
Equillium Company Profile
Equillium, Inc, a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.
Further Reading: What are Closed-End Mutual Funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.